# Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels

> **NCT00522470** · PHASE4 · COMPLETED · sponsor: **Baskent University**

## Conditions studied

- Type 2 Diabetes Mellitus
- Obesity

## Interventions

- **DRUG:** rosiglitazone

## Key facts

- **NCT ID:** NCT00522470
- **Lead sponsor:** Baskent University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2008-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00522470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00522470, "Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00522470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*